Publications 2025

Gjølberg TT, Mester S, Calamera G, Telstad JS, Sandlie I, Andersen JT (2025)
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
BioDrugs, 39 (3), 373-409
DOI 10.1007/s40259-025-00708-2, PubMed 40156757

Mester S, Chan C, Lustig M, Foss S, Jansen JHM, Leangen Herigstad M, Evers M, Nilsen J, Reiding KR, A Damen JM, Burger R, Grevys A, Dalhus B, Valerius T, Sandlie I, Leusen JHW, Andersen JT (2025)
Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life
PNAS Nexus, 4 (2), pgaf042
DOI 10.1093/pnasnexus/pgaf042, PubMed 40041621

Publications 2024

Foss S, Sakya SA, Aguinagalde L, Lustig M, Shaughnessy J, Cruz AR, Scheepmaker L, Mathiesen L, Ruso-Julve F, Anthi AK, Gjølberg TT, Mester S, Bern M, Evers M, Bratlie DB, Michaelsen TE, Schlothauer T, Sok D, Bhattacharya J, Leusen J, Valerius T, Ram S, Rooijakkers SHM, Sandlie I, Andersen JT (2024)
Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria
Nat Commun, 15 (1), 2007
DOI 10.1038/s41467-024-46321-9, PubMed 38453922

Publications 2023

Jørstad ØK, Foss S, Gjølberg TT, Mester S, Nyquist-Andersen M, Sivertsen MS, Fossum D, Gleditsch E, Moe MC, Andersen JT (2023)
Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties
Int J Retina Vitreous, 9 (1), 65
DOI 10.1186/s40942-023-00507-3, PubMed 37936232

Lustig M, Chan C, Jansen JHM, Bräutigam M, Kölling MA, Gehlert CL, Baumann N, Mester S, Foss S, Andersen JT, Bastian L, Sondermann P, Peipp M, Burger R, Leusen JHW, Valerius T (2023)
Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
Front Immunol, 14, 1178817
DOI 10.3389/fimmu.2023.1178817, PubMed 37346044

Publications 2022

Gjølberg TT, Frick R, Mester S, Foss S, Grevys A, Høydahl LS, Jørstad ØK, Schlothauer T, Sandlie I, Moe MC, Andersen JT (2022)
Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life
Commun Biol, 5 (1), 832
DOI 10.1038/s42003-022-03787-x, PubMed 35982144

Gjølberg TT, Lode HE, Melo GB, Mester S, Probst C, Sivertsen MS, Jørstad ØK, Andersen JT, Moe MC (2022)
A Silicone Oil-Free Syringe Tailored for Intravitreal Injection of Biologics
Front Ophthalmol (Lausanne), 2, 882013
DOI 10.3389/fopht.2022.882013, PubMed 38983507

Grevys A, Frick R, Mester S, Flem-Karlsen K, Nilsen J, Foss S, Sand KMK, Emrich T, Fischer JAA, Greiff V, Sandlie I, Schlothauer T, Andersen JT (2022)
Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life
iScience, 25 (2), 103746
DOI 10.1016/j.isci.2022.103746, PubMed 35118359

Publications 2021

Mester S, Evers M, Meyer S, Nilsen J, Greiff V, Sandlie I, Leusen J, Andersen JT (2021)
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
MAbs, 13 (1), 1893888
DOI 10.1080/19420862.2021.1893888, PubMed 33691596

Aaen KH, Anthi AK, Sandlie I, Nilsen J, Mester S, Andersen JT (2021)
The neonatal Fc receptor in mucosal immune regulation
Scand J Immunol, 93 (2), e13017
DOI 10.1111/sji.13017, PubMed 33351196